Non-invasive glucose monitor developer Know Labs (OTCQB:KNWN) announced today that it added two executives to its leadership team.
Seattle-based Know Labs — which aims to make the first non-invasive glucose monitor cleared by the FDA — added Steven Kent as its new chief product officer, along with Peter Conley as its CFO and SVP of intellectual property.
“Pete and Steve bring tremendous expertise that will help us refine and execute our IP strategy, product innovation, and machine learning progress,” Know Labs CEO Phil Bosua said in a news release. “By strengthening our executive leadership team, we are better positioned to tackle the milestones needed for the FDA clearance process.”
The company designed its Bio-RFID technology to use spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It can be integrated into wearable, mobile or bench-top form factors. Know Labs’ first application of the technology comes in the form of a non-invasive glucose monitor.
Conley has over 34 years of corporate finance and equity capital markets experience, having most recently served as senior managing director and head of intellectual property banking at Boustead Securities. He previously co-founded and served as COO of ipCreate.
Kent joins Know Labs with more than 10 years of experience as an inventor, entrepreneur and leader in medical and health-focused consumer systems. He was most recently head of health partnerships and corporate strategy at Oura and previously founded and served as CEO of Invicta Medical.
“It is exciting to witness our organization grow,” Know Labs CMO Dr. James Anderson said. “I’ve been through this process several times in my career. As we get closer to FDA submission and clearance, the amount of work increases across multiple disciplines; and this requires expertise in each discipline. Having experienced and highly qualified individuals is critical for our success.”